ECSP14025965A - Procedimiento de fabricación de una forma de dosificación farmacéutica que comprende nifedipina y candesartán cilexetilo - Google Patents

Procedimiento de fabricación de una forma de dosificación farmacéutica que comprende nifedipina y candesartán cilexetilo

Info

Publication number
ECSP14025965A
ECSP14025965A ECIEPI201425965A ECPI201425965A ECSP14025965A EC SP14025965 A ECSP14025965 A EC SP14025965A EC IEPI201425965 A ECIEPI201425965 A EC IEPI201425965A EC PI201425965 A ECPI201425965 A EC PI201425965A EC SP14025965 A ECSP14025965 A EC SP14025965A
Authority
EC
Ecuador
Prior art keywords
pharmaceutical dosage
dosage form
candesartan
cylexethyl
procedure
Prior art date
Application number
ECIEPI201425965A
Other languages
English (en)
Spanish (es)
Inventor
Sarah Just
Adrian Funke
Martina Smikalla
Peter Kleinebudde
Jochen Zeitler
Daniela Brock
Markus Wirges
Andreas Meeners
Rolf-Anton Boeggering
GüNTER MEYER
Klaus Knop
Original Assignee
Poli Nutri Alimentos S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48289160&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP14025965(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Poli Nutri Alimentos S A filed Critical Poli Nutri Alimentos S A
Publication of ECSP14025965A publication Critical patent/ECSP14025965A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/005—Coating of tablets or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/06—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ECIEPI201425965A 2012-05-07 2014-11-06 Procedimiento de fabricación de una forma de dosificación farmacéutica que comprende nifedipina y candesartán cilexetilo ECSP14025965A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12167035 2012-05-07
EP13151946 2013-01-18

Publications (1)

Publication Number Publication Date
ECSP14025965A true ECSP14025965A (es) 2015-12-31

Family

ID=48289160

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201425965A ECSP14025965A (es) 2012-05-07 2014-11-06 Procedimiento de fabricación de una forma de dosificación farmacéutica que comprende nifedipina y candesartán cilexetilo

Country Status (27)

Country Link
US (1) US9539176B2 (en, 2012)
EP (1) EP2846777B1 (en, 2012)
JP (1) JP6231553B2 (en, 2012)
KR (1) KR20150007297A (en, 2012)
CN (1) CN104507459A (en, 2012)
AR (1) AR090940A1 (en, 2012)
AU (1) AU2013258273A1 (en, 2012)
BR (1) BR112014027618A2 (en, 2012)
CA (1) CA2872542A1 (en, 2012)
CL (1) CL2014002988A1 (en, 2012)
CO (1) CO7190241A2 (en, 2012)
CR (1) CR20140511A (en, 2012)
DO (1) DOP2014000251A (en, 2012)
EA (1) EA201492026A1 (en, 2012)
EC (1) ECSP14025965A (en, 2012)
ES (1) ES2612532T3 (en, 2012)
GT (1) GT201400245A (en, 2012)
HK (1) HK1204292A1 (en, 2012)
IL (1) IL235040A0 (en, 2012)
IN (1) IN2014DN09045A (en, 2012)
MX (1) MX2014013320A (en, 2012)
PE (1) PE20142284A1 (en, 2012)
PH (1) PH12014502469A1 (en, 2012)
SG (1) SG11201406363VA (en, 2012)
TW (1) TW201410266A (en, 2012)
UY (1) UY34786A (en, 2012)
WO (1) WO2013167453A1 (en, 2012)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9244004B2 (en) * 2013-08-08 2016-01-26 Stichting Sron—Netherlands Institute For Space Research Method and system for inspection of composite assemblies using terahertz radiation
US10071482B2 (en) 2015-08-19 2018-09-11 Ford Global Technologies, Llc Robotic vehicle painting instrument including a terahertz radiation device
US10365229B2 (en) * 2015-12-31 2019-07-30 Kaiser Optical Systems, Inc. Real-time characterization of pharmaceutical tablet coatings using Raman spectroscopy
DE102016222667A1 (de) * 2016-11-17 2018-05-17 Robert Bosch Gmbh Verfahren zum Betrieb einer Anlage zum Herstellen von pharmazeutischen Produkten
US10323932B1 (en) 2017-12-28 2019-06-18 Ford Motor Company System for inspecting vehicle bodies
JP7263047B2 (ja) 2019-02-25 2023-04-24 沢井製薬株式会社 フィルムコーティング錠剤
CN110411978B (zh) * 2019-07-26 2020-05-22 中国农业大学 一种物料均匀性检测设备及检测方法
CN115192538B (zh) * 2022-08-02 2023-09-15 沈阳信康药物研究有限公司 一种压制包衣型硝苯地平缓释片及其制备方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1670827C3 (de) 1967-03-20 1974-10-24 Bayer Ag, 5090 Leverkusen 4-(2'-Nitrophenyl)-2,6-dimethyl-3,5-dicarbmethoxy-1,4-dihydropyridin
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4426019A (en) 1981-10-15 1984-01-17 The Coca-Cola Company Membrane seal and knife combination for a post-mix beverage dispensing system
US4576604A (en) 1983-03-04 1986-03-18 Alza Corporation Osmotic system with instant drug availability
NZ206600A (en) 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US5082668A (en) 1983-05-11 1992-01-21 Alza Corporation Controlled-release system with constant pushing source
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4948592A (en) 1986-05-09 1990-08-14 Alza Corporation Pulsed drug delivery
DE3720757A1 (de) 1987-06-24 1989-01-05 Bayer Ag Dhp-manteltablette
US4931285A (en) 1988-04-28 1990-06-05 Alza Corporation Aqueous based pharmaceutical coating composition for dosage forms
DK0386440T3 (da) 1989-02-11 1992-09-14 Bayer Ag Lægemidler med kontrolleret afgivelse af virksomt stof
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5656650A (en) 1990-12-14 1997-08-12 Smithkline Beecham Corp. Angiotensin II receptor blocking compositions
JP3398379B2 (ja) 1990-12-14 2003-04-21 スミスクライン・ビーチャム・コーポレイション アンジオテンシンｉｉ受容体遮断組成物
US5160744A (en) 1991-06-27 1992-11-03 Alza Corporation Verapmil therapy
US5178867A (en) 1991-08-19 1993-01-12 Alza Corporation Dosage form for delivering drug in short-time period
US5543154A (en) 1991-12-27 1996-08-06 Merck & Co., Inc. Controlled release nifedipine delivery device
CA2125251C (en) 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
DE19747261A1 (de) 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
WO2000059481A1 (en) 1999-04-06 2000-10-12 Pharmaquest Ltd. PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF d-threo-METHYLPHENIDATE AND A SECOND CNS STIMULANT
US20040115134A1 (en) 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
EP1413315A4 (en) 2001-08-03 2006-08-16 Takeda Pharmaceutical DRUGS WITH CONTINUOUS RELEASE
EP1438027A1 (en) 2001-10-25 2004-07-21 DepoMed, Inc. Methods of treatment using a gastric retained losartan dosage
US20030161882A1 (en) 2002-02-01 2003-08-28 Waterman Kenneth C. Osmotic delivery system
WO2003080057A1 (fr) 2002-03-27 2003-10-02 Bayer Aktiengesellschaft Comprime-noyau de taille reduite contenant de la nifedipine
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
US8029822B2 (en) 2003-05-22 2011-10-04 Osmotica Kereskedelmi és Seolgáltató KFT Rupturing controlled release device having a preformed passageway
ATE457166T1 (de) 2003-07-24 2010-02-15 Wockhardt Ltd Orale zusammensetzungen zur behandlung von diabetes
WO2005070398A2 (en) 2004-01-23 2005-08-04 Ranbaxy Laboratories Limited Pharmaceutical compositions of candesartan cilexetil stabilized with co-solvents
WO2005079751A2 (en) 2004-01-23 2005-09-01 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of candesartan cilexetil
WO2005084648A1 (en) 2004-02-27 2005-09-15 Ranbaxy Laboratories Limited Pharmaceutical compositions comprising candesartan cilexetil
TW200534879A (en) 2004-03-25 2005-11-01 Bristol Myers Squibb Co Coated tablet formulation and method
TWI354569B (en) 2004-05-28 2011-12-21 Bristol Myers Squibb Co Coated tablet formulation and method
DE102004062475A1 (de) 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
DE202006020979U1 (de) 2005-05-10 2011-08-05 Teva Pharmaceutical Industries Ltd. Stabiles mikronisiertes Candesartan-Cilexetil
DE102005031577A1 (de) * 2005-07-06 2007-01-11 Bayer Healthcare Ag Pharmazeutische Darreichungsformen enthaltend eine Wirkstoffkombination von Nifedipin und/oder Nisoldipin und einem Angiotensin-II Antagonisten
EP2040780B1 (en) 2006-07-03 2016-01-06 Novo Nordisk A/S Coupling for injection devices
KR100888131B1 (ko) 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
WO2008045006A1 (en) 2006-10-11 2008-04-17 Fako Ilaclari A. S. Formulations of candesartan
WO2008065097A2 (en) 2006-11-28 2008-06-05 Laboratorios Liconsa, S.A. Stabilized solid pharmaceutical composition of candesartan cilexetil
JP5351490B2 (ja) 2007-10-25 2013-11-27 バイエル薬品株式会社 ニフェジピン含有有核錠剤およびその製法
DE102008059206A1 (de) * 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
CN103370064A (zh) 2010-09-03 2013-10-23 百时美施贵宝公司 使用水溶性抗氧化剂的药物制剂

Also Published As

Publication number Publication date
IN2014DN09045A (en, 2012) 2015-05-22
US9539176B2 (en) 2017-01-10
JP6231553B2 (ja) 2017-11-15
AR090940A1 (es) 2014-12-17
ES2612532T3 (es) 2017-05-17
IL235040A0 (en) 2014-12-31
GT201400245A (es) 2015-08-25
EA201492026A1 (ru) 2015-09-30
CL2014002988A1 (es) 2015-03-13
BR112014027618A2 (pt) 2017-06-27
SG11201406363VA (en) 2014-11-27
MX2014013320A (es) 2015-08-10
DOP2014000251A (es) 2014-12-31
CN104507459A (zh) 2015-04-08
WO2013167453A1 (en) 2013-11-14
CO7190241A2 (es) 2015-02-19
PH12014502469A1 (en) 2014-12-22
CR20140511A (es) 2014-12-02
EP2846777A1 (en) 2015-03-18
AU2013258273A1 (en) 2014-11-13
PE20142284A1 (es) 2014-12-17
CA2872542A1 (en) 2013-11-14
UY34786A (es) 2013-11-29
JP2015515999A (ja) 2015-06-04
US20130309302A1 (en) 2013-11-21
TW201410266A (zh) 2014-03-16
EP2846777B1 (en) 2016-10-26
HK1204292A1 (en) 2015-11-13
KR20150007297A (ko) 2015-01-20

Similar Documents

Publication Publication Date Title
ECSP14025965A (es) Procedimiento de fabricación de una forma de dosificación farmacéutica que comprende nifedipina y candesartán cilexetilo
UY32260A (es) Forma de dosificación farmacéutica que comprende nifedipino o nisoldipino y un antagonista de angiotensina ii y/o diuretico
UY34306A (es) Pirimidinas condensadas sustituidas y su uso
DOP2014000255A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
DOP2012000299A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
BR112013019223A2 (pt) forma de dosagem para liberação modificada, processo para a fabricação de um comprimido e processo para a fabricação de uma forma de dosagem oral
CR20130008A (es) Anillos condensados de pirimidinas y triazinas y su uso para el tratamiento y/o profilaxis de enfermedades cardiovasculares
UY34918A (es) Nuevos ácidos 5-aminotetrahidroquinolin-2-carboxílicos y su uso
BR112012028788A2 (pt) fabricação de grânulos sem ativos
CO6940408A2 (es) Composiciones en forma de comprimido de disolución rápida para administración vaginal
ES2524385R1 (es) Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH
GT201500035A (es) Composición farmacéutica oral en forma de microesferas y proceso de elaboración
ES2408343R1 (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
ES2415029A8 (es) Composición farmacéutica y uso de un anticuerpo para preparar un medicamento destinado a inhibir la producción o amplificar la eliminación de la proteína P24.
CO7111317A2 (es) Método para el tratamiento de enfermedades ginecológicas
MX364704B (es) Inhibidores de replicacion viral, su proceso de preparacion y sus usos terapeuticos.
CU20140126A7 (es) Procedimiento de fabricación de una forma de dosificación farmacéutica que comprende nifedipina y candesartán cilexetilo
BR112014032037A2 (pt) formulações para a preparação de comprimidos de liberação imediata para uso oral contendo uma baixa dosagem de mifepristona para o tratamento de endometriose, comprimidos desse modo obtidos e seu processo de preparação
PE20170201A1 (es) Formas de dosificacion farmaceutica
EP2799043A4 (en) VAGINAL RING WITH MELOXICAM AND A MEANS FOR MODULATING THE RELEASE OF AN ACTIVE AGGREGATE FOR USE AS A CONTINUOUS RECIPIENT OF PREVENTION IN WOMEN